Shirley Michelle Shiller, DO
Regarding precision medicine in gastrointestinal (GI) cancers, pathologists are working to determine which patient populations should undergo which molecular tests.
State of the Science Summit™ on Gastrointestinal Cancers, Shirley Michelle Shiller, DO, a pathologist at Baylor University Medical Center, discussed the clinical application of precision medicine in GI cancer.
For patients with colorectal cancer (CRC), Shiller said that testing is recommended for KRAS
, and BRAF
mutations. These 3 mutations constitute over 50% of the genetic changes in CRC, she added. Identifying these markers can guide therapy, provide prognostic data, and can be relevant in Lynch syndrome work-up. BRAF
V600E is the relevant target in the colon that does not necessarily apply in other sites of origin, and does allow a patient to get targeted therapy, Shiller explained.
... to read the full story